Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Other Working Capital Changes (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Other Working Capital Changes for 11 consecutive years, with $52.3 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes rose 192.32% to $52.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.0 million through Dec 2025, up 93.46% year-over-year, with the annual reading at -$3.0 million for FY2025, 93.46% up from the prior year.
  • Other Working Capital Changes for Q4 2025 was $52.3 million at BeOne Medicines, up from -$70.4 million in the prior quarter.
  • The five-year high for Other Working Capital Changes was $150.2 million in Q1 2021, with the low at -$349.0 million in Q4 2021.
  • Average Other Working Capital Changes over 5 years is -$23.1 million, with a median of -$11.0 million recorded in 2021.
  • Peak annual rise in Other Working Capital Changes hit 4206.25% in 2021, while the deepest fall reached 492.32% in 2021.
  • Over 5 years, Other Working Capital Changes stood at -$349.0 million in 2021, then skyrocketed by 88.83% to -$39.0 million in 2022, then skyrocketed by 39.49% to -$23.6 million in 2023, then crashed by 140.05% to -$56.6 million in 2024, then surged by 192.32% to $52.3 million in 2025.
  • According to Business Quant data, Other Working Capital Changes over the past three periods came in at $52.3 million, -$70.4 million, and $2.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.